Search

Your search keyword '"Lokhorst, H. M"' showing total 11 results
Start Over Author "Lokhorst, H. M" Journal haematologica
11 results on '"Lokhorst, H. M"'

1. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Author

de Haart, S. J., primary, Holthof, L., additional, Noort, W. A., additional, Minnema, M. C., additional, Emmelot, M. E., additional, Aarts-Riemens, T., additional, Doshi, P., additional, Sasser, K., additional, Yuan, H., additional, de Bruijn, J., additional, Martens, A. C. M., additional, van de Donk, N. W. C. J., additional, Lokhorst, H. M., additional, Groen, R. W. J., additional, and Mutis, T., additional

Published
2016
Full Text
View/download PDF

2. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Author

Drent, E., primary, Groen, R. W. J., additional, Noort, W. A., additional, Themeli, M., additional, Lammerts van Bueren, J. J., additional, Parren, P. W. H. I., additional, Kuball, J., additional, Sebestyen, Z., additional, Yuan, H., additional, de Bruijn, J., additional, van de Donk, N. W. C. J., additional, Martens, A. C. M., additional, Lokhorst, H. M., additional, and Mutis, T., additional

Published
2016
Full Text
View/download PDF

3. Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

Author

Lokhorst, H. M., primary, van der Holt, B., additional, Cornelissen, J. J., additional, Kersten, M. J., additional, van Oers, M., additional, Raymakers, R., additional, Minnema, M. C., additional, Zweegman, S., additional, Bos, G., additional, Schaap, N., additional, Wittebol, S., additional, de Weerdt, O., additional, Ammerlaan, R., additional, and Sonneveld, P., additional

Published
2015
Full Text
View/download PDF

7. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

Author

Scheid, C., primary, Sonneveld, P., additional, Schmidt-Wolf, I. G. H., additional, van der Holt, B., additional, Jarari, L. e., additional, Bertsch, U., additional, Salwender, H., additional, Zweegman, S., additional, Blau, I. W., additional, Vellenga, E., additional, Weisel, K., additional, Pfreundschuh, M., additional, Jie, K.-S., additional, Neben, K., additional, van de Velde, H., additional, Duehrsen, U., additional, Schaafsma, M. R., additional, Lindemann, W., additional, Kersten, M. J., additional, Peter, N., additional, Hanel, M., additional, Croockewit, S., additional, Martin, H., additional, Wittebol, S., additional, Bos, G. M., additional, van Marwijk-Kooy, M., additional, Wijermans, P., additional, Goldschmidt, H., additional, and Lokhorst, H. M., additional

Published
2013
Full Text
View/download PDF

9. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

Author

Rozemuller, H., primary, van der Spek, E., additional, Bogers-Boer, L. H., additional, Zwart, M. C., additional, Verweij, V., additional, Emmelot, M., additional, Groen, R. W., additional, Spaapen, R., additional, Bloem, A. C., additional, Lokhorst, H. M., additional, Mutis, T., additional, and Martens, A. C., additional

Published
2008
Full Text
View/download PDF

10. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial

Author

Sonneveld, P., primary, van der Holt, B., additional, Segeren, C. M., additional, Vellenga, E., additional, Croockewit, A. J., additional, Verhoef, G. E.G., additional, Cornelissen, J. J., additional, Schaafsma, M. R., additional, van Oers, M. H.J., additional, Wijermans, P. W., additional, Westveer, P. H.M., additional, and Lokhorst, H. M., additional

Published
2007
Full Text
View/download PDF

11. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.

Author

van der Spek E, Bloem AC, Sinnige HA, and Lokhorst HM

Subjects
Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Clinical Trials, Phase I as Topic, Dexamethasone administration & dosage, Dexamethasone adverse effects, Doxorubicin administration & dosage, Doxorubicin adverse effects, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Multiple Myeloma complications, Simvastatin adverse effects, Vincristine administration & dosage, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Drug Resistance, Neoplasm drug effects, Multiple Myeloma drug therapy, Simvastatin administration & dosage
Abstract

In a prospective phase II study, we evaluated the combination of high dose simvastatin and VAD chemotherapy in patients with refractory or relapsed multiple myeloma. Although treatment was feasible with mild side effects, only 1 of 12 patients achieved a partial response. According to our predefined criteria this was insufficient to continue the study.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results